{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"PFS was defined as the time interval between the entry into trial and occurrence of one of the following events: progression of disease (PD) or death as a result of primary central nervous system lymphoma (PCNSL). Participants who were withdrawn from the study without documented progression and for whom there existed case report form (CRF) evidence that evaluations had been made, were censored at the date of last tumor assessment when participant was known to be progression free. Participants without postbaseline tumor assessments but known to be alive were censored at the time of randomization. PD required a ≥25% increase in the contrast-enhanced lesion seen on MRI as compared with baseline or best response (comparison should be made to the smallest of multiple lesions); progression of ocular disease as indicated by an increase in vitreous cell count or progressive retinal or optic nerve infiltration, appearance of any new lesion or site of disease during or at the end of therapy.","groups":[{"description":"Participants received single doses of rituximab 750 mg/m\\^2 IV at Weeks 1 through 5, and 7, 9, 11, 14, 16, 18, 20, and 22; cytarabine 2 g/m\\^2 IV every 24 hours for 2 doses at Weeks 11 and 22; and single doses of MTX 8 g/m\\^2 IV at Weeks 3, 5, 7, 9, 14, 16, 18, and 20.","id":"OG000","title":"Rituximab, Cytarabine, and MTX"}],"populationDescription":"Due to early study termination, all efficacy data were documented by data listings only, no data analysis was performed.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Progression-Free Survival (PFS)","type":"SECONDARY"}